Key Takeaways Pediatrix authorized a $250M share buyback after generating$245M in operating cash flow in TTM.The company raised 2025 adjusted EBITDA guidance to $245-$255M from $220-$240M.Profitability improved with divestitures, boosting return on capital to 10.6%.Pediatrix Medical Group, Inc. (MD) has stepped up its commitment to shareholder returns with a new $250 million share repurchase authorization, underpinned by solid cash generation. Over the past 12 months, the company produced$245 million in o ...